Merrimack Pharmaceuticals Inc.'s stockholders, at a March 30 special meeting, approved the sale of oncology assets to Ipsen SA.

The company will give Ipsen its commercialized pancreatic cancer product, Onivyde, including U.S. commercialization rights and its licensing agreements with Shire PLC.

In addition, the deal covers Merrimack's generic doxorubicin hydrochloride liposome injection, Doxil, which is advanced under a development, license and supply agreement with Actavis LLC.

Merrimack expects the transaction to be completed in the coming days.